Induction of hepatitis E virus anti-ORF3 antibodies from systemic administration of a muscle-specific Adeno-associated virus (AAV) vector
The hepatitis E virus (HEV) is a major global health problem, leading to large outbreaks in the developing world and chronic infections in the developed world. HEV is a non-enveloped virus, which circulates in the blood in a quasi-enveloped form. The quasi-envelope protects HEV particles from neutra...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
27 January 2022
|
| In: |
Viruses
Year: 2022, Volume: 14, Issue: 2, Pages: 1-14 |
| ISSN: | 1999-4915 |
| DOI: | 10.3390/v14020266 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/v14020266 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4915/14/2/266 
|
| Author Notes: | Lars Maurer, Jihad El Andari, Kleopatra Rapti, Laura Spreyer, Eike Steinmann, Dirk Grimm and Viet Loan Dao Thi |
| Summary: | The hepatitis E virus (HEV) is a major global health problem, leading to large outbreaks in the developing world and chronic infections in the developed world. HEV is a non-enveloped virus, which circulates in the blood in a quasi-enveloped form. The quasi-envelope protects HEV particles from neutralising anti-capsid antibodies in the serum; however, most vaccine approaches are designed to induce an immune response against the HEV capsid. In this study, we explored systemic in vivo administration of a novel synthetic and myotropic Adeno-associated virus vector (AAVMYO3) to express the small HEV phosphoprotein ORF3 (found on quasi-enveloped HEV) in the musculature of mice, resulting in the robust and dose-dependent formation of anti-ORF3 antibodies. Neutralisation assays using the serum of ORF3 AAV-transduced mice showed a modest inhibitory effect on the infection of quasi-enveloped HEV in vivo, comparable to previously characterised anti-ORF3 antibodies used as a control. The novel AAVMYO3 capsid used in this study can serve as a versatile platform for the continued development of vector-based vaccines against HEV and other infectious agents, which could complement traditional vaccines akin to the current positive experience with SARS-CoV-2. |
|---|---|
| Item Description: | Gesehen am 20.04.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1999-4915 |
| DOI: | 10.3390/v14020266 |